Clinical trial · Observational
Treatment of Desmoid Fibromatosis With Arterial Embolization
Treatment of Desmoid Fibromatosis With Arterial Embolization: Retrospective and Prospective Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by several retrospective and prospective studies. These studies report promising results through the use of chemoembolization, that is, arterial embolization using particles loaded with chemotherapy. Instead, the type of treatment we propose would consist of injection of embolizing material without the use of chemotherapy, based on the positive results we have consistently reported over the years on arterial embolization of musculoskeletal tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Desmoid Fibromatosis | Desmoid Fibromatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| embolization therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Performed embolization
- interventionNames
- Procedure: embolization therapy
Primary outcomes (3)
- measure
- Reduction of pain (VAS score)
- timeFrame
- 1 year
- description
- Clinical assessment regarding pain by Visual Analogue Scale (VAS) score (0-100 mm), in which 0 represents no pain, and 100 represents maximum pain imaginable.
- measure
- Reduction of antalgic therapy (mg)
- timeFrame
- 1 year
- description
- Mean reduction in the use of pain medications evaluated in mg of active ingredient taken daily before the treatment and at follow-up.
- measure
- Volume reduction in cm³
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of both sexes aged ≥ 12 years * Fibromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups) * Patients not eligible for surgery or cryoablation * Patients who have had embolization surgery for fibromatosis desmoide from 01/01/2023 to date and all new patients listed for this type of treatment. * Signature of informed consent to the study Exclusion Criteria: * Patients with life expectancy \<3 months or severely impaired status functional status (ASA 4) * Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT) * Patients with coagulation deficiency or plateletopenic disease * Patients with documented active infection * Incompatibility to performing MRI examination.
References
Publications (0)
Data not yet available